Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 is a phase 1/2 interventional study registered as NCT04787042 by Simcha IL-18, Inc., with 316 participants planned, started 2021-08-06 and due to reach its primary completion in 2025-06-30. Interventions recorded: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab. Conditions listed: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.